(Information sent by the signatory company)
MIRAMAR, Fla., Feb. 20, 2024/PRNewswire/ — Kimera® Labs Inc, a privately held clinical-stage biotechnology company, is pleased to announce the first publication of exosomes and a novel innovative neuronal delivery method in the prestigious family from scientific journals Nature. The article, “Use of low-intensity transcranial focused ultrasound for targeted delivery of stem cell-derived exosomes to the brain,” was published on October 18, 2023 in Nature Scientific Reports. A team of world-class scientists from City of Hope, Regenesis Project and Kimera® Labs collaborated to demonstrate that MSC-derived exosomes made by Kimera® can cross the blood-brain barrier (BBB) ??using a focused ultrasound wave in a rat model . A series of in vivo animal studies were conducted at City of Hope. Study findings published in Nature Scientific Reports concluded that a statistically significant amount of Kimera® exosomes penetrated the BBB using ultrasound focused on a specific region of the rat brain.
The Kimera® neural study employing exosomes combined with focused ultrasound is considered a significant advance by the scientific community in the challenging field of targeted brain delivery. “At Kimera® we are pleased that the world-renowned characterization of our anti-inflammatory and regenerative exosomes is instrumental in this neuronal breakthrough. Publication of this work required more than two years of collaboration and funding between Kimera labs® and our world-class team.” We sincerely thank the 18 scientists involved in this work for their strong collaborative effort that was finally recognized by the editors of the journal Nature. We look forward to conducting further experiments in this field for the submission of multiple INDs to address various indications in neuronal dysfunction for future human trials,” said Duncan Ross PhD, co-founder and CEO of Kimera® Labs and co-author of the paper.
The scientific and clinical opportunities presented by this innovative study for neurology are exciting. “This study demonstrates an accessible, non-invasive means of targeted delivery across the blood-brain barrier,” said Dr. Sheldon Jordan, professor of Neurology at UCLA and leader of the Regenesis Project. “The demonstrated ability to selectively deliver exosomes to brain sites non-invasively with accessible technology should inspire the development of protocols to facilitate neuromodulation with payloads including small molecules and epigenome-modifying factors,” he added.
The article can be consulted at https://www.nature.com/articles/s41598-023-44785-1
Kimera® Labs received its first Phase I/IIa IND approval to conduct human clinical trials for post-Covid patients on May 16, 2023. The company is in the process of advancing further neural scientific and clinical developments with its exosomes that They use focused ultrasound.
Logo – https://mma.prnewswire.com/media/1014981/Kimera_Exosomes_Logo_Blue_2x_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/kimera-labs-inc-publica-una-nueva-orientacion-cerebral-de-exosomas-en-nature-scientific-reports-302066001.html
